MediWound Ltd. (MDWD) - Form 20-F Summary
Business Context and Reporting Period
Company: MediWound Ltd.
Reporting Period: Fiscal year ended December 31, 2024.
Business Overview: MediWound is a biopharmaceutical company developing enzymatic therapeutics for tissue repair. Its flagship product, NexoBrid, is approved in over 40 countries for eschar removal in severe burns. The company is advancing EscharEx, a Phase III candidate for chronic wound debridement, and MW005 for basal cell carcinoma. Operations are headquartered in Yavne, Israel, with a new manufacturing facility completed in August 2024, expected to increase capacity sixfold by end of 2025.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 (USD) | 2023 (USD) |
|---|---|---|
| Total Revenues | $20.2 million | $18.7 million |
| Cost of Revenues | $17.6 million | $15.1 million |
| Gross Profit | $2.6 million | $3.6 million |
| Operating Loss | $(19.4) million | $(15.3) million |
| Net Loss | $(30.2) million | $(6.7) million |
| Cash & Equivalents | $9.2 million | $11.9 million |
| Total Cash, Deposits & Restricted Cash | $43.6 million | $41.7 million |
| Accumulated Deficit | $(205.0) million | $(174.8) million |
Revenue Composition (2024):
- Development Services (BARDA/DoD): $13.1 million (65%)
- Sales of Products: $6.8 million (34%)
- Licenses/Royalties: $0.3 million (1%)
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss increased significantly from $6.7 million in 2023 to $30.2 million in 2024. This was primarily driven by a $10.7 million non-cash financial expense related to the revaluation of warrants following a 75% rise in the company's share price during 2024.
- Revenue Growth: Total revenue grew 8% year-over-year, driven by increased sales to partner Vericel and new contracts with the U.S. Department of Defense (DoD).
- Margin Compression: Gross margin declined from 19% in 2023 to 13% in 2024. Cost of revenues as a percentage of total revenue increased from 81% to 87%, attributed to higher fixed costs associated with scaling production and a shift in revenue mix toward lower-margin development services.
- Capital Raise: In July 2024, the company raised $25 million via a private placement (PIPE) and entered a collaboration with Mölnlycke Health Care AB.
Guidance, Outlook, and Risks
Outlook & Liquidity: Management believes existing cash and cash equivalents ($43.6 million) are sufficient to fund operations and capital expenditures for at least 12 months. The company expects to continue incurring substantial net losses as it advances clinical trials for EscharEx and scales manufacturing.
Key Developments:
- NexoBrid: FDA approved pediatric indication (newborn to 18 years) in August 2024. Received Category III CPT code effective July 2025.
- EscharEx: Initiated the global pivotal Phase III "VALUE" trial for venous leg ulcers in February 2025. Received €16.25 million in blended funding from the European Innovation Council (EIC) in July 2024.
- Manufacturing: New GMP facility in Yavne completed; commissioning underway with full capacity expected by end of 2025.
Material Risks:
- Geopolitical Instability: Ongoing conflict in Israel (Hamas, Hezbollah, Iran) poses risks to operations, workforce availability, and supply chain continuity. The company's sole manufacturing site is in Yavne, Israel.
- Supply Chain Concentration: Reliance on a single supplier (Challenge Bioproducts Corporation Ltd. in Taiwan) for the key intermediate drug substance (bromelain SP).
- Regulatory & Clinical: Uncertainty regarding the success of EscharEx Phase III trials and potential delays in regulatory approvals for new indications.
- Financial: Continued history of net losses and dependence on government contracts (BARDA/DoD) which can be terminated at the government's discretion.
Investor Verification Checklist
- Warrant Liability Impact: Verify the non-cash nature of the $10.7 million warrant revaluation expense and its impact on the reported net loss versus cash burn.
- Manufacturing Timeline: Confirm the timeline for regulatory approval of the new Yavne facility and the transition of production to ensure no supply disruption for NexoBrid.
- Geopolitical Exposure: Assess the specific contingency plans for the Yavne manufacturing site and the sole-source supplier in Taiwan amidst regional conflicts.
- EscharEx Trial Progress: Monitor enrollment rates and interim data from the Phase III VALUE trial initiated in early 2025.
- Government Contract Stability: Review the terms of BARDA and DoD contracts regarding termination rights and future funding certainty.